Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Article Is Abbott's January Pullback a Good Time to Buy? By Thomas Hughes. Article Published: 1/24/2026. 
Article Highlights - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making the stock look attractively valued. The move — driven more by market angst than by any clear operational weakness — appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
A major force in the crypto world is quietly becoming one of gold's most aggressive buyers — and most investors have no idea it's happening.
A longtime gold analyst says profits from a leading stablecoin operation are being funneled into physical gold at a scale that could materially impact supply and demand. After a recent meeting with insiders, he began outlining what this trend could mean for gold prices and a small group of companies positioned to benefit. Read the full gold briefing here The buy zone lines up with price action from 2022–2024, when Abbott was recovering from a post‑COVID revenue contraction; during that period, institutions accumulated the shares. Abbott Laboratories Growth Accelerates Though some metrics missed expectations in its Q4 results and guidance, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth lagged by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. By segment, the results highlighted the resilience of Abbott's diversified healthcare portfolio. Nutrition fell nearly 9% and Diagnostics also contracted, but that weakness was offset by solid growth in Established Pharmaceuticals and MedTech. Established Pharmaceuticals grew roughly 9%, driven by generics and emerging markets, and MedTech climbed about 12.3%, showing strength across sub‑segments. Margins improved thanks to a favorable product mix, strength in MedTech, lower COVID‑19 sales and operational efficiencies. Some margin metrics still came in a bit below the most optimistic analyst forecasts, but the overall trajectory is positive. Management expects earnings to rise another ~10% in 2026, outpacing revenue growth and supporting its capital‑return plans. Capital returns are central to the buy case. Abbott is a Dividend King, having increased its payout for more than 50 consecutive years, and it should have the capacity to continue that trend. After the pullback the stock yields roughly 2.5%, and management pays less than half of consensus earnings as dividends, leaving room for share buybacks — an important offset to share‑based dilution. Analysts Point to Robust Rebound Potential Some analysts highlighted the revenue miss, but there were no major rating or price‑target cuts during the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth, and that the medium‑term growth outlook remains meaningful. The MarketBeat consensus share price target implies upside of as much as ~30%, which could put the stock near or above its previous highs; even the low‑end targets imply modest upside from current levels. Key catalysts include an expanding MedTech portfolio, AI integration across operations and products, margin expansion, and strategic acquisitions. The proposed acquisition of Exact Sciences, for example, would broaden Abbott's revenue and profit streams and expand its product pipeline. That said, the recent decline has been sharp and could deepen. Institutions that accumulated shares through 2025 are likely buyers at discounted levels, which should provide some support. Early technical support appears in the $105–$110 range, though it is not yet confirmed. Shares could test the low end of the buy zone — potentially the mid‑$90s — before staging a rebound.
| 
